報價延遲最少15分鐘:2024/05/17 01:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.25 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.91/-0.59
|
|
企業價值
502.81M
|
| 資產負債 |
|
每股賬面淨值
0.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.99M
|
|
每股收益
0.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/17 01:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy. |